解离素金属蛋白酶9的研究进展  

Research progress in dissociation metalloproteinase 9

作　　者：董冉杰 李三强[1] DONG Ran-jie;LI San-qiang(Medical School,Henan University of Science and technology,Liver Injury and Repair of Molecular Medicine Key Experiments,Luoyang 471003,Henan Province China)

机构地区：[1]河南科技大学医学院肝脏损伤与修复分子医学重点实验室,河南洛阳471003

出　　处：《中国临床药理学杂志》2018年第20期2473-2476,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然基金资助项目(81201558);河南省科技创新杰出青年基金资助项目(2018JQ0006);河南省高校科技创新团队基金资助项目(181RTSTHN026);河南科技大学创新团队基金资助项目(2015XTD003);河南省科技攻关基金资助项目(172102310693)

摘　　要：解离素金属蛋白酶9(ADAM9)属于I型跨膜糖蛋白,是ADAM家族中的重要一员,其独特结构和生物学功能成为近年来研究的热点。ADAM9参与多种疾病的发生发展过程,其在各种恶性肿瘤中的表达升高。此外,ADAM9还参与受精、肌生成、神经发生和细胞间的相互作用等生理过程。Dissociation metalloproteinase 9 （ ADAM9 ）, belongs to the type I transmembrane glycoprotein, is an important member of the ADAM family and. Its unique structure and biological function have become hot spots in recent years. ADAM9 is involved in the development of various diseases, especially in various malignant tumors. In addition, it participates in physiological processes such as fertilization, myogenesis, neurogenesis and cell- cell interaction.

关 键 词：解离素金属蛋白酶9 恶性肿瘤 视网膜新生血管化 生理过程 

分 类 号：R97[医药卫生—药品]